DMARDs and Biologics
Information about DMARDs and Biologics in the treatment of psoriasis.
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) are a class of drugs which can stop the progression of rheumatoid and psoriatic arthritis. These drugs often have serious side effects, but given the importance of not letting arthritis damage joints, the possible complications are often acceptable (especially when the choice is between being able to move and not moving). These drugs may, in some cases of severe psoriasis with or without arthritis, also be useful in reducing the skin symptoms of the disease.
Biologics are drugs (or devices) which are produced by living organisms. These are, these days, typically proteins. This area of drug research is where most of the psoriasis drugs under development are coming from. Creating specialized proteins which interfere with specific parts of the human immune system suspected to play a role in creating psoriasis symptoms.
Reviewed Treatments and Information
Unreviewed Treatments and Information
ABX-IL8 (made by Abgenix)
Homepage
March 5, 2001, Abgenix Press Release
May 14, 2002, Press Release detailing the discontinuation of research
Abgenix Cancels Clinical Trials for Psoriasis Drug (May 15, 2002)
New Treatments on the Horizon for Psoriasis
March 5, 2001, Abgenix Press Release
May 14, 2002, Press Release detailing the discontinuation of research
Abgenix Cancels Clinical Trials for Psoriasis Drug (May 15, 2002)
New Treatments on the Horizon for Psoriasis
Amevive™ (alefacept, LFA3TIP — made by Biogen)
May 25, 1999 Press Release
Release delayed until at least 2003
Psoriasis Drugs Prepare to Go Head-to-Head (June 15, 2001)
Liquent Technology Speeds International Registration Filing for Promising New Psoriasis Therapy (August 22, 2001)
Mixed Ending to Stocks’ Rough Day (June 14, 2002)
New Psoriasis Drug Available (January 31, 2003)
Biogen volatile in after-hours (June 13, 2002)
FDA Committee Endorses New Psoriasis Treatment (May 24, 2002)
Biogen recibe la calificación Respuesta Completa de la FDA para la aplicación de AMEVIVE (alefacept) (June 14, 2002)
Biogen presenta una solicitud para la aprobación de AMEVIVE (alefacept) a comienzos de 2003 (September 13, 2002)
Biogen’s SEC Filings
Nursing Spectrum (March 13, 2003)
FDA: Biogen’s Amevive carries infection risk (May 22, 2002)
Lou Dobbs Moneyline (May 23, 2002)
New Psoriasis Drug Available (January 31, 2003)
New Psoriasis Drugs Seem Promising In Tests (March 9, 2001)
New Treatments on the Horizon for Psoriasis
Psoriasis Relief, at a Price (March 4, 2003)
Biogen Stock
FDA OKs Unique New Psoriasis Treatment (January 31, 2003)
Cincinatti Enquirer Business Highlights (May 27, 2002)
USACHPPM Health Information Operations Update
(February 7, 2003)
Release delayed until at least 2003
Psoriasis Drugs Prepare to Go Head-to-Head (June 15, 2001)
Liquent Technology Speeds International Registration Filing for Promising New Psoriasis Therapy (August 22, 2001)
Mixed Ending to Stocks’ Rough Day (June 14, 2002)
New Psoriasis Drug Available (January 31, 2003)
Biogen volatile in after-hours (June 13, 2002)
FDA Committee Endorses New Psoriasis Treatment (May 24, 2002)
Biogen recibe la calificación Respuesta Completa de la FDA para la aplicación de AMEVIVE (alefacept) (June 14, 2002)
Biogen presenta una solicitud para la aprobación de AMEVIVE (alefacept) a comienzos de 2003 (September 13, 2002)
Biogen’s SEC Filings
Nursing Spectrum (March 13, 2003)
FDA: Biogen’s Amevive carries infection risk (May 22, 2002)
Lou Dobbs Moneyline (May 23, 2002)
New Psoriasis Drug Available (January 31, 2003)
New Psoriasis Drugs Seem Promising In Tests (March 9, 2001)
New Treatments on the Horizon for Psoriasis
Psoriasis Relief, at a Price (March 4, 2003)
Biogen Stock
FDA OKs Unique New Psoriasis Treatment (January 31, 2003)
Cincinatti Enquirer Business Highlights (May 27, 2002)
USACHPPM Health Information Operations Update
(February 7, 2003)Anti-CD4
Anti-IL2R (Simulect®, basiliximab)
“Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)” Salim et al. Br J Dermatol 2000 Nov;143(5):1121-2.
“Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody.” Owen and Harrison Clin Exp Dermatol 2000 May;25(3):195-7.
“Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody.” Owen and Harrison Clin Exp Dermatol 2000 May;25(3):195-7.
Arthritis Drugs Provide Psoriasis Relief on WebMD
Biologic Therapy for Psoriasis (abstract) from the Archives of Dermatology
Biologics Approved for Treatment of Psoriasis
Biospace News: Psoriasis
Enbrel (etanercept — made by Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals)
Homepage
National Psoriasis Foundation — Nov 16, 1999
National Psoriasis Foundation — Aug 3, 2000
Amgen Stock
An Enbrel Study
Immunex one of “55 Great Employers for Asian Americans”
Enbrel Effective in Patients with Psoriatic Arthritis and Psoriasis
Immunex Offers Data That Enbrel Has Broader Potential (November 12, 2001)
Strong Enbrel Sales Help Immunex Match Estimates (October 17, 2001)
Immunex Could Be Gearing Up for Growth (July 5, 2001)
Drug Helps Psoriatic Arthritis Patients
FDA Approves Etanercept (Enbrel®) for Treatment of Psoriatic Arthritis
FDA Assigns ‘Priority Review’ Status to ENBREL(R) (etanercept) sBLA For Treatment of Psoriatic Arthritis — Priority Review is Granted Based on Need for Disease Treatment (Sep. 17, 2001)
Enbrel Expands Use to Include Psoriatic Arthritis
National Psoriasis Foundation — Nov 16, 1999
National Psoriasis Foundation — Aug 3, 2000
Amgen Stock
An Enbrel Study
Immunex one of “55 Great Employers for Asian Americans”
Enbrel Effective in Patients with Psoriatic Arthritis and Psoriasis
Immunex Offers Data That Enbrel Has Broader Potential (November 12, 2001)
Strong Enbrel Sales Help Immunex Match Estimates (October 17, 2001)
Immunex Could Be Gearing Up for Growth (July 5, 2001)
Drug Helps Psoriatic Arthritis Patients
FDA Approves Etanercept (Enbrel®) for Treatment of Psoriatic Arthritis
FDA Assigns ‘Priority Review’ Status to ENBREL(R) (etanercept) sBLA For Treatment of Psoriatic Arthritis — Priority Review is Granted Based on Need for Disease Treatment (Sep. 17, 2001)
Enbrel Expands Use to Include Psoriatic Arthritis
The Heartbreak of Psoriasis
HU1124
HumaT4 (Made by Intracel)
HuMax-CD4 (Made by Genmab A/S)
Genmab to Present HuMax-CD4 Phase II Safety Data at EULAR (June 11, 2002)
HuMax-IL15 (Made by Genmab A/S)
Genmab HuMax-IL15 Effective Against Psoriasis in Mouse Study (July 1, 2002)
Cerca del 60% de los pacientes ha obtenido el valor ACR20 con HuMax-IL15 de Genmab (September 9, 2002)
Cerca del 60% de los pacientes ha obtenido el valor ACR20 con HuMax-IL15 de Genmab (September 9, 2002)
IDEC-114 (made by IDEC Pharmaceuticals)
IDEC Pharmaceuticals Partnerships
IDEC Pharmaceuticals Products
New Treatments on the Horizon for Psoriasis
Testing halted for psoriasis after disappointing results
Yahoo! Finance
IDEC Pharmaceuticals Products
New Treatments on the Horizon for Psoriasis
Testing halted for psoriasis after disappointing results
Yahoo! Finance
MEDI-507 (siplizumab — made by MedImmune)
Psoriasis Drugs Prepare to Go Head-to-Head (June 15, 2001)
Monoclonals Get Slammed
New Hope for the Heartbreak of Psoriasis
No More Itching in N’Awlins
P38 Kinase Inhibitors
Psoriasis Drugs Prepare to Go Head-to-Head (June 15, 2001)
Psoriasis Relief, at a Price
Raptiva™ (efalizumab, anti-CD11a, used to be called Xanelim — made by Genentech and XOMA)
Important note! On April 10th, 2009, the National Psoriasis Foundation sent out the following email:
The maker of the psoriasis drug Raptiva (efalizumab) is pulling the drug from the U.S. market because of its association with a rare and usually fatal brain infection. Psoriasis patients taking Raptiva should immediately talk to their doctor about finding an alternative treatment, says the National Psoriasis Foundation. Stopping Raptiva abruptly could lead to a severe psoriasis flare, so patients should be sure to talk to their doctors before they stop treatment.
Genentech, the drug’s maker, has announced a phased withdrawal of the drug, which is associated with a higher risk of developing progressive multifocal leukoencephalopathy (PML), which can attack people with weakened immune systems.
Genentech researchers say that Raptiva’s effects typically wear off by 12 weeks after the patient’s last dose. “The risk of developing PML after 12 weeks should be greatly reduced,” said Bruce Bebo, Ph.D., Psoriasis Foundation research director. “Raptiva has a fairly short life in the immune system once the patient stops using the drug.”
Genentech, the drug’s maker, has announced a phased withdrawal of the drug, which is associated with a higher risk of developing progressive multifocal leukoencephalopathy (PML), which can attack people with weakened immune systems.
Genentech researchers say that Raptiva’s effects typically wear off by 12 weeks after the patient’s last dose. “The risk of developing PML after 12 weeks should be greatly reduced,” said Bruce Bebo, Ph.D., Psoriasis Foundation research director. “Raptiva has a fairly short life in the immune system once the patient stops using the drug.”
The email included a link to Genentech’s press release about this very important news. The National Psoriasis Foundation itself doesn’t have much to say.
Jim Hargrove’s clinical trial experiences
Homepage
Just the Boost Genentech Needs?
PROHOST’s Version of the March 5, 2001 Information
Treatment attacks psoriasis on a molecular level (final section on the page)
XOMA Press Release (March 5, 2001)
XOMA Press Release (April 4, 2001)
New Treatments on the Horizon for Psoriasis
Serono Stock
Cincinatti Enquirer Business Digest (April 6, 2002)
Remicade® (infliximab — made by Centocor)
Remicade
Press Release
Made by Centocor
Infliximab Effective for Psoriatic Arthritis
P&T Forum (April, 2002)
New Treatments on the Horizon for Psoriasis
Study: Arthritis Drug Shows Early Promise in Relieving Psoriasis Symptoms
WSVN-TV
Press Release
Press Release
Made by Centocor
Infliximab Effective for Psoriatic Arthritis
P&T Forum (April, 2002)
New Treatments on the Horizon for Psoriasis
Study: Arthritis Drug Shows Early Promise in Relieving Psoriasis Symptoms
WSVN-TV
Press Release
Say Farewell to the Psoriasis Heartbreak
Solid Gold Sales
Xerecept® (hCRF, Neurobiological Technologies, Inc.)
Zenapax® (anti-CD25, daclizumab — made by PDLI)
“Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis” Krueger et al. J Am Acad Dermatol 2000 Sep;43(3):448-58.
Research on use of Zenapax® for psoriasis halted
Research on use of Zenapax® for psoriasis halted